Pacira Biosciences
A Focus on Pain Management | Pacira Pharmaceuticals, Inc..
Launch date
Employees
Market cap
$587m
Enterprise valuation
$831m (Public information from Sep 2024)
Share price
$14.65 PCRX
San Diego California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 421m | 542m | 667m | 675m | 693m | 654m | 663m |
| % growth | - | 29 % | 23 % | 1 % | 3 % | (6 %) | 1 % |
| EBITDA | 66.9m | 145m | 121m | 171m | 214m | 212m | 264m |
| % EBITDA margin | 16 % | 27 % | 18 % | 25 % | 31 % | 32 % | 40 % |
| Profit | 146m | 42.0m | 15.9m | 42.0m | 72.6m | 36.2m | 73.0m |
| % profit margin | 35 % | 8 % | 2 % | 6 % | 10 % | 6 % | 11 % |
| EV / revenue | 7.0x | 5.8x | 3.5x | 2.7x | 1.2x | 1.1x | 0.7x |
| EV / EBITDA | 44.3x | 21.7x | 19.4x | 10.6x | 3.9x | 3.2x | 1.8x |
| R&D budget | 59.4m | 55.5m | 84.8m | 76.3m | - | - | - |
| R&D % of revenue | 14 % | 10 % | 13 % | 11 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
$85.0m | Series A | ||
| N/A | N/A | IPO | |
$27.5m | Post IPO Debt | ||
* | N/A | $250m | Post IPO Convertible |
| Total Funding | $85.0m | ||
Related Content
Recent News about Pacira Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Pacira Biosciences
Edit
ACQUISITION by Pacira Biosciences Mar 2019
ACQUISITION by Pacira Biosciences Oct 2021
exited
ACQUISITION by Flexion Therapeutics Jul 2017
